SPY003-207 in Healthy Volunteers
Launched by SPYRE THERAPEUTICS, INC. · Mar 12, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The SPY003-207 clinical trial is a study designed to test a new drug called SPY003-207 in healthy volunteers. This is an early-stage trial, meaning it's one of the first times this drug is being tested in people. The main goals are to see if the drug is safe to use, how well it is tolerated, and how the body processes it. The study is currently looking for participants aged 18 to 65 who are in good health and willing to attend regular visits at the research facility.
To be eligible, you must be a healthy adult, meaning you don't have any significant health issues or diseases. You'll also need to commit to staying at the study site for a certain period and comply with all testing requirements. If you've had any significant health problems, a history of drug or alcohol abuse, or certain allergic reactions, you may not be able to participate. If you join the trial, you can expect to receive either the study drug or a placebo (a sugar pill that doesn't contain the active drug) and will be monitored closely throughout the process to ensure your safety.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy men and women
- • Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits
- Exclusion Criteria:
- • Participation in more than one cohort
- • Evidence of clinically significant abnormality or disease
- • Known history of illicit drug use or drug abuse, harmful alcohol use or alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study drug
- • History of severe allergic reactions or hypersensitivity
- • Donation or loss of \>1 unit of whole blood within 1 month prior to dosing
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is an innovative biopharmaceutical company dedicated to advancing the treatment of complex diseases through the development of cutting-edge therapeutics. With a strong focus on harnessing novel drug discovery approaches and precision medicine, Spyre Therapeutics aims to address unmet medical needs in various therapeutic areas, including oncology and rare diseases. The company is committed to rigorous clinical research and collaboration with healthcare professionals to ensure the safety and efficacy of its investigational therapies, ultimately striving to improve patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
Patients applied
Trial Officials
Deanna Nguyen, MD
Study Chair
Spyre Therapeutics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported